Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$16.70
Change (%) Stock is Up 0.06 (0.36%)
Volume21,639
Data as of 08/25/16 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
08/18/16Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
08/17/16Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
08/10/16Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results
08/08/16Eiger BioPharmaceuticals to Present at the 2016 Wedbush PacGrow Healthcare Conference on August 17th
Upcoming EventsMore >>
DateTitle
11/29/16
Eiger BioPharmaceuticals at Oppenheimer Life Sciences Summit
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.